Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
Objective. To describe the immunogenicity and safety of a tetravalent dengue vaccine (TAK-003) in healthy adolescents living in Mexico City, an area considered non-endemic for dengue (NCT03341637). Methods. Participants aged 12–17 years were randomized 3:1 to receive two doses (Month 0 and Month 3)...
Main Authors: | Shibadas Biswal, Jorge Fernando Mendez Galvan, Mercedes Macias Parra, Juan-Francisco Galan-Herrera, Monica Belisa Carrascal Rodriguez, Esteban Patricio Rodriguez Bueno, Manja Brose, Martina Rauscher, Inge LeFevre, Derek Wallace, Astrid Borkowski |
---|---|
Format: | Article |
Language: | English |
Published: |
Pan American Health Organization
2021-06-01
|
Series: | Revista Panamericana de Salud Pública |
Subjects: | |
Online Access: | https://iris.paho.org/handle/10665.2/54151 |
Similar Items
-
The Immunogenicity and Safety of CYD-Tetravalent Dengue Vaccine (CYD-TDV) in Children and Adolescents: A Systematic Review
by: Raksheeth Agarwal, et al.
Published: (2017-04-01) -
Dengue virus type-3 envelope protein domain III; expression and immunogenicity
by: Hossein Fahimi, et al.
Published: (2014-11-01) -
Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands
by: Guy El Helou, et al.
Published: (2020-06-01) -
Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys
by: Galler R., et al.
Published: (2005-01-01) -
Development of Sanofi Pasteur tetravalent dengue vaccine
by: Jean Lang
Published: (2012-10-01)